Logo Medical Science Monitor Basic Research

Call: 1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research

03 November 1997

Role of dopaminergic receptor agonists in the treatment of Parkinson's disease

Zygmunt Jamrozik, Piotr Janik

Med Sci Monit 1997; 3(6): RA948-955 :: ID: 501846

Abstract

The efficiency of long time treatment by levodop of Parkinson's disease (PD) is limited to occurrence of side syndromes in the form of movement disorders such as: fluctuations, diskinesia, the decrease of effectiveness of the drug. The causes of their occurrence connected with loss of dopaminergic cells, pharmacodynamics, pharmacokinetic of levodop, changes in affinity of dopamine receptors (D), pathology of other structures outside the nigrostrial pathways. The discovery of the family of dopamine receptors D1, D2, D3, D4 and D5 and their differentiated effect on the functions of exrapyramidal system allowed the use of the strategy of more selective reaction on particular receptors. Dopamine receptor agonists (DAAG) have some positive characteristics from the clinical point of view and theoretical comparison to levodop. Those drugs are not metabolized to active chemicals, do not produce toxic metabolites or free radicals, their effectiveness in a smaller degree is depended on degree of damage of presynaptic elements. DAAG effectively brings back the balance in the neurotransmission of neuropeptides in striatum and decrease rotation of endogenic dopamine. Among actually available DAAG at least three have potential neuroprotective action. Former clinical xperiments show that use of this drugs is particularly desirable in two groups of patients. First consists of young patients, that had been not treated yet, particularly successible to fast occurrence of levodopic complications, in whom the use of DAAG in monotherapy allows to decrease the risk of far complications. The second group consists of patients treaded with levadop, with developed side symptoms, which cannot be satisfactorily control with the help of antycholinergic drugs, amontadine, benzodiazapine.

Keywords: basal ganglia, dopaminergic receptor agonists

Comments

Most Viewed Current Articles

31 Dec 1969 : Original article  

Outcome of 24 Weeks of Combined Schroth and Pilates Exercises on Cobb Angle, Angle of Trunk Rotation, Chest...

DOI :10.12659/MSMBR.920449

Med Sci Monit Basic Res 2020; 26:e920449

31 Dec 1969 : Original article  

Analysis of Psychological and Sleep Status and Exercise Rehabilitation of Front-Line Clinical Staff in the ...

DOI :10.12659/MSMBR.924085

Med Sci Monit Basic Res 2020; 26:e924085

31 Dec 1969 : Review article  

A Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against...

DOI :10.12659/MSMBR.929207

Med Sci Monit Basic Res 2021; 27:e929207

31 Dec 1969 : Clinical Research  

Effects of Cognitive Task Training on Dynamic Balance and Gait of Patients with Stroke: A Preliminary Rando...

DOI :10.12659/MSMBR.925264

Med Sci Monit Basic Res 2020; 26:e925264

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor Basic Research eISSN: 2325-4416
Medical Science Monitor Basic Research eISSN: 2325-4416